Krystal Biotech, Inc. KRYS Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Krystal Biotech, Inc. (KRYS) reported comprehensive income (loss), net of tax, attributable to parent of $53.17M in Q1 2026.
- How has Krystal Biotech, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Krystal Biotech, Inc.'s comprehensive income (loss), net of tax, attributable to parent increased by 46.4% year-over-year, from $36.31M to $53.17M.
- What is the long-term trend for Krystal Biotech, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a 31.1% compound annual growth rate (CAGR), from -$69.74M to $206.16M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- The total change in company value including both net profit and unrealized market gains or losses.
- How do you interpret comprehensive income (loss), net of tax, attributable to parent?
- A higher value indicates overall growth in the company's net worth, encompassing both operational success and investment performance.
- How does comprehensive income (loss), net of tax, attributable to parent compare across companies?
- Standard accounting measure for total equity movement; comparable across firms with significant investment portfolios.